NASDAQ:BMRA

Biomerica - BMRA Stock Forecast, Price & News

$1.98

+0.06 (+3.13%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.87
▼
$1.99
50-Day Range: $1.86
▼
$3.00
52-Week Range: $1.84
▼
$5.25

Volume: 7,823 shs
Average Volume: 57,045 shs
Market Capitalization: $33.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Biomerica (NASDAQ:BMRA) Stock

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Stock News Headlines

March 8, 2023 | finance.yahoo.com

Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed

March 7, 2023 | finance.yahoo.com

Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock

March 25, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 3, 2023 | finance.yahoo.com

Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock

March 2, 2023 | finance.yahoo.com

Biomerica Announces Proposed Underwritten Public Offering of Common Stock

February 20, 2023 | finance.yahoo.com

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

January 10, 2023 | finance.yahoo.com

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

January 10, 2023 | finance.yahoo.com

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

March 25, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

December 24, 2022 | seekingalpha.com

Biomerica: H.Pylori Announcements Important To Keep An Eye On, Reaffirm Hold

December 8, 2022 | finance.yahoo.com

Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

December 1, 2022 | finance.yahoo.com

We Think Shareholders May Consider Being More Generous With Biomerica, Inc.'s (NASDAQ:BMRA) CEO Compensation Package

October 17, 2022 | finanznachrichten.de

Biomerica, Inc.: Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022

October 14, 2022 | finance.yahoo.com

Sneakerheads Will Be Happy: Nike Is Ready to Penalize Accounts Reselling Its Products - Yahoo Finance

October 14, 2022 | seekingalpha.com

Avenue, IMARA lead healthcare gainers; Galecto, Travere among losers - Seeking Alpha

October 14, 2022 | marketwatch.com

Biomerica stock leaps as Walmart expands sales of Aware Breast Self Exam to its stores - MarketWatch

October 14, 2022 | finance.yahoo.com

Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 - Yahoo Finance

October 13, 2022 | globenewswire.com

Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 - GlobeNewswire

October 13, 2022 | finance.yahoo.com

Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022

October 11, 2022 | finance.yahoo.com

Those who invested in Biomerica (NASDAQ:BMRA) five years ago are up 39%

September 30, 2022 | it.tmcnet.com

Biomerica's Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon

September 29, 2022 | benzinga.com

Thinking about buying stock in BigBear.ai, Bed Bath & Beyond, Atara Biotherapeutics, Stabilis Solutions, - Benzinga

September 29, 2022 | benzinga.com

Biomerica's Aware Breast Self Exam and EZ Detect Colon Disease Test Now Available On Amazon And Fulfilled - Benzinga

September 29, 2022 | finance.yahoo.com

Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon

September 26, 2022 | globenewswire.com

Blood Testing Market to hit USD 123 Billion by 2030, says Global Market Insights Inc. - GlobeNewswire

September 14, 2022 | globenewswire.com

LifeMD Expands Primary Care Platform's Diagnostic - GlobeNewswire

September 9, 2022 | seekingalpha.com

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Company Calendar

Last Earnings: 1/13/2023
Today: 3/25/2023
Next Earnings (Estimated): 4/13/2023
Fiscal Year End: 5/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BMRA
CUSIP: N/A
CIK: 73290
Web: www.biomerica.com
Phone: (949) 645-2111
Fax: 949-553-1231
Employees: 66
Year Founded: 1971

Profitability

EPS (Most Recent Fiscal Year): ($0.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,530,000.00
Net Margins: -34.58%
Pretax Margin: -34.48%
Return on Equity: -66.11%
Return on Assets: -44.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.59
Quick Ratio: 3.42

Sales & Book Value

Annual Sales: $18.87 million
Price / Sales: 1.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.65 per share
Price / Book: 3.05

Miscellaneous

Outstanding Shares: 16,810,000
Free Float: 14,173,000
Market Cap: $33.28 million
Optionable: Not Optionable
Beta: -0.53

Social Links

Key Executives

Zackary S. Irani
Chairman & Chief Executive Officer

Gary Lu
Chief Financial & Accounting Officer

Robert Carlson
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BMRA Stock - Frequently Asked Questions

How have BMRA shares performed in 2023?: Biomerica's stock was trading at $3.35 at the beginning of 2023. Since then, BMRA stock has decreased by 40.9% and is now trading at $1.98.
View the best growth stocks for 2023 here.
When is Biomerica's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 13th 2023.
View our BMRA earnings forecast.
How were Biomerica's earnings last quarter?: Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings results on Friday, January, 13th. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $1.48 million for the quarter. Biomerica had a negative net margin of 34.58% and a negative trailing twelve-month return on equity of 66.11%.
What other stocks do shareholders of Biomerica own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?: Biomerica trades on the NASDAQ under the ticker symbol "BMRA."
Who are Biomerica's major shareholders?: Biomerica's stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (3.12%), Geode Capital Management LLC (0.67%), Russell Investments Group Ltd. (0.47%), Hollencrest Capital Management (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste, Mark A Sirgo and Zackary S Irani.
View institutional ownership trends.
How do I buy shares of Biomerica?: Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biomerica's stock price today?: One share of BMRA stock can currently be purchased for approximately $1.98.
How much money does Biomerica make?: Biomerica (NASDAQ:BMRA) has a market capitalization of $33.28 million and generates $18.87 million in revenue each year. The company earns $-4,530,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.
How can I contact Biomerica?: Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The official website for the company is www.biomerica.com. The company can be reached via phone at (949) 645-2111, via email at jnesbett@institutionalms.com, or via fax at 949-553-1231.

This page (NASDAQ:BMRA) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial